Nephros (NEPH)
(Delayed Data from NSDQ)
$1.80 USD
-0.01 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.80 USD
-0.01 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0.00% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Nephros Inc. (NEPH) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Nephros Inc. (NEPH) Maintain Its Recent Price Strength
by Zacks Equity Research
Nephros Inc. (NEPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Nephros Inc. (NEPH) a Good Fit for "Trend Investing"
by Zacks Equity Research
Nephros Inc. (NEPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Nephros Inc. (NEPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 57.14% and 1.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 33.33% and 1.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nephros Inc. (NEPH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for August 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Chembio (CEMI) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Chembio (CEMI) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Nephros Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nephros has been struggling lately, but the selling pressure may be coming to an end soon.
OraSure Technologies (OSUR) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Abbott (ABT) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Abbott (ABT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance
by Zacks Equity Research
The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.
Nephros Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nephros has been struggling lately, but the selling pressure may be coming to an end soon.
Top Ranked Momentum Stocks to Buy for October 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23rd